EQS-Adhoc: Viromed Medical AG completes acquisition of pharmedix GmbH
Werte in diesem Artikel
EQS-Ad-hoc: Viromed Medical AG / Key word(s): Takeover/Mergers & Acquisitions Viromed Medical AG completes acquisition of pharmedix GmbH
Pinneberg, 20 December 2024 – Today, Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) completed the announced acquisition of pharmedix GmbH by notarized purchase agreement. The acquisition is effective as of 1 January 2025. Following the successful acquisition of pharmedix GmbH, Viromed Medical AG now expects consolidated revenues in the low double-digit million euro range for the 2025 financial year, a significant increase over the previous year.
Contact Viromed Medical AG Uwe Perbandt End of Inside Information
20-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Viromed Medical AG |
Flensburger Straße 18 | |
25421 Pinneberg | |
Germany | |
Phone: | +49 4101 809960 |
E-mail: | kontakt@viromed-medical.de |
Internet: | https://www.viromed-medical-ag.de/ |
ISIN: | DE000A3MQR65 |
WKN: | A3MQR6 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg |
EQS News ID: | 2056023 |
End of Announcement | EQS News Service |
|
2056023 20-Dec-2024 CET/CEST
Ausgewählte Hebelprodukte auf Fonterelli SPAC 2
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Fonterelli SPAC 2
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Fonterelli SPAC 2 AG Inhaber-Akt
Analysen zu Fonterelli SPAC 2 AG Inhaber-Akt
Keine Analysen gefunden.